Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT3306 (pembrolizumab biosimilar) in Stage IV non-squamous NSCLC
NCT06280196Phase 3Terminated
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Bio-Thera Solutions, Ltd.. Started Jul 2024; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06280196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06280196.